Deciphering von hippel-lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Shen, H C Jennifer ^a   Adem, Asha ^a   Ylaya, Kris ^a   Wilson, Arianne ^a   He, Mei ^a   Lorang, Dominique ^a   Hewitt, Stephen M ^a   Pechhold, Klaus ^b   Harlan, David M ^b   Lubensky, Irina A ^a   Schmidt, Laura S ^a,c   Linehan, W Marston ^a   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; TRANSCRIPTION FACTOR PDX 1; VON HIPPEL LINDAU PROTEIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VHL PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; ENDOCRINE CELL; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PANCREAS DISEASE; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS TUMOR; PROTEIN DEFICIENCY; PROTEIN FUNCTION; STEM CELL; TUMOR VASCULARIZATION; VON HIPPEL LINDAU DISEASE; ANIMAL; CELL LINEAGE; CYTOLOGY; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PANCREAS; PHYSIOLOGY; UPREGULATION;

MUS; MUS MUSCULUS;

ANIMALS; CELL LINEAGE; GENE SILENCING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; PANCREAS; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 64549146243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004897     Document Type: Article

References (50)

1. Couch V, Lindor NM, Karnes PS, Michels VV (2000) von Hippel-Lindau disease. Mayo Clin Proc 75: 265-272.
2. Latif F, Tory K, Gnarra J, Yao M, Duh FM, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320.
3. Chen F, Kishida T, Yao M, Hustad T, Glavac D, et al. (1995) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5: 66-75.
4. Glavac D, Neumann HP, Wittke C, Jaenig H, Masek O, et al. (1996) Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet 98: 271-280.
5. Linehan WM, Lerman MI, Zbar B (1995) Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273: 564-570.
6. Friedrich CA (2001) Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 10: 763-767.
7. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, et al. (2001) von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10: 1019-1027.
8. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, et al. (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-919.
9. Pioli PA, Rigby WF (2001) The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J Biol Chem 276: 40346-40352.
10. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93: 10595-10599.
11. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
12. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, et al. (2001) Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10: 1029-1038.
13. Flamme I, Krieg M, Plate KH (1998) Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol 153: 25-29.
14. Cohen HT, Zhou M, Welsh AM, Zarghamee S, Scholz H, et al. (1999) An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 266: 43-50.
15. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17: 5629-5639.
16. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D (1997) The von Hippel-Lindau gene product inhibits vascular permeability factor/ vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 272: 27509-27512.
17. Esteban-Barragan MA, Avila P, Alvarez-Tejado M, Gutierrez MD, Garcia-Pardo A, et al. (2002) Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res 62: 2929-2936.
18. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5: 64-70.
19. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, et al. (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1: 959-968.
20. Tang N, Mack F, Haase VH, Simon MC, Johnson RS (2006) pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 26: 2519-2530.
21. Kessler PM, Vasavada SP, Rackley RR, Stackhouse T, Duh FM, et al. (1995) Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1: 457-466.
22. Richards FM, Schofield PN, Fleming S, Maher ER (1996) Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5: 639-644.
23. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, et al. (1997) Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 94: 9102-9107.
24. Haase VH, Glickman JN, Socolovsky M, Jaenisch R (2001) Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 98: 1583-1588.
25. Ma W, Tessarollo L, Hong SB, Baba M, Southon E, et al. (2003) Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 63: 5320-5328.
26. Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, et al. (2004) Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol 24: 9038-9047.
27. Pfander D, Kobayashi T, Knight MC, Zelzer E, Chan DA, et al. (2004) Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development 131: 2497-2508.
28. Rankin EB, Tomaszewski JE, Haase VH (2006) Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 66: 2576-2583.
29. Hough DM, Stephens DH, Johnson CD, Binkovitz LA (1994) Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol 162: 1091-1094.
30. Neumann HP, Dinkel E, Brambs H, Wimmer B, Friedburg H, et al. (1991) Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 101: 465-471.
31. Binkovitz LA, Johnson CD, Stephens DH (1990) Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol 155: 501-505.
32. Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, et al. (1998) Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 124: 1153-1159.
33. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, et al. (1998) Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153: 223-231.
34. Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, et al. (1999) Z/ AP, a double reporter for cre-mediated recombination. Dev Biol 208: 281-292.
35. Gannon M, Shiota C, Postic C, Wright CV, Magnuson M (2000) Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26: 139-142.
36. Park SK, Haase VH, Johnson RS (2007) von Hippel Lindau tumor suppressor regulates hepatic glucose metabolism by controlling expression of glucose transporter 2 and glucose 6-phosphatase. Int J Oncol 30: 341-348.
37. Gu G, Dubauskaite J, Melton DA (2002) Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129: 2447-2457.
38. Mohr VH, Vortmeyer AO, Zhuang Z, Libutti SK, Walther MM, et al. (2000) Histopathology and molecular genetics of multiple cysts and microcystic (serous) adenomas of the pancreas in von Hippel-Lindau patients. Am J Pathol 157: 1615-1621.
39. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686.
40. Herrera PL, Nepote V, Delacour A (2002) Pancreatic cell lineage analyses in mice. Endocrine 19: 267-278.
41. Alpert LC, Truong LD, Bossart MI, Spjut HJ (1988) Microcystic adenoma (serous cystadenoma) of the pancreas. A study of 14 cases with immunohistochemical and electron-microscopic correlation. Am J Surg Pathol 12: 251-263.
42. Shorten SD, Hart WR, Petras RE (1986) Microcystic adenomas (serous cystadenomas) of pancreas. A clinicopathologic investigation of eight cases with immunohistochemical and ultrastructural studies. Am J Surg Pathol 10: 365-372.
43. Morohoshi T, Held G, Kloppel G (1983) Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 7: 645-661.
44. Nyongo A, Huntrakoon M (1985) Microcystic adenoma of the pancreas with myoepithelial cells. A hitherto undescribed morphologic feature. Am J Clin Pathol 84: 114-120.
45. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, et al. (2007) Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142: 814-818; discussion 818 e811-812.
46. Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, et al. (2007) von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med 4: e60.
47. Kurban G, Hudon V, Duplan E, Ohh M, Pause A (2006) Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66: 1313-1319.
48. Hong SB, Furihata M, Baba M, Zbar B, Schmidt LS (2006) Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Lab Invest 86: 664-675.
49. Thurston G, Baluk P, Hirata A, McDonald DM (1996) Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol 271: H2547-2562.
50. Shen HC, Rosen JE, Yang LM, Savage SA, Burns AL, et al. (2008) Parathyroid tumor development involves deregulation of homeobox genes. Endocr Relat Cancer 15: 267-275.